Skip to main content

Cometriq FDA Approval History

FDA Approved: Yes (First approved November 29, 2012)
Brand name: Cometriq
Generic name: cabozantinib
Dosage form: Capsules
Company: Exelixis, Inc.
Treatment for: Thyroid Cancer

Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Development timeline for Cometriq

DateArticle
Nov 29, 2012Approval FDA Approves Cometriq (cabozantinib) to Treat Rare Type of Thyroid Cancer
Aug 30, 2012Exelixis Provides Update on ODAC Panel for Cabozantinib
Jul 30, 2012FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer
May 30, 2012Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Medullary Thyroid Cancer

See also

Cometriq (cabozantinib) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer